Oncotelic Therapeutics (OTCQB: OTLC) has launched an artificial intelligence-powered GMP manufacturing services platform aimed at addressing a critical bottleneck in biotechnology: the high cost and complexity of building Good Manufacturing Practice (GMP) infrastructure. The platform, announced in June, integrates the company's PDAOAI architecture, digital batch records, and intelligent robotics developed with partner TechForce Robotics. It targets emerging biotechs, contract development and manufacturing organizations (CDMOs), cell and gene therapy developers, and radiopharmaceutical manufacturers that cannot justify building full GMP facilities in-house.
The same AI-GMP capabilities are already operational inside Oncotelic's SAPU manufacturing base, positioning the launch as both a pipeline accelerator and a potential new revenue stream. For small and virtual biotech companies, the journey from discovery to clinical trials often stalls at manufacturing. Regulatory documentation, batch records, quality systems, and scalable production require significant investment and expertise. Oncotelic's platform aims to provide a cost-effective, scalable solution that leverages artificial intelligence to streamline operations and ensure compliance.
According to the company, the platform uses PDAOAI to optimize manufacturing processes, reduce errors, and improve efficiency. Digital batch records replace paper-based systems, enhancing traceability and audit readiness. Robotics from TechForce Robotics further automate tasks, reducing manual labor and contamination risks. Oncotelic believes this integrated approach can significantly lower the barriers to GMP manufacturing for smaller players, enabling them to advance their pipelines more quickly and cost-effectively.
The launch comes as the biotech industry faces increasing pressure to accelerate development timelines while controlling costs. Manufacturing remains one of the most capital-intensive aspects of drug development, often requiring specialized facilities and expertise that are out of reach for many startups. By offering GMP services on a fee-for-service basis, Oncotelic could capture a share of this growing market while also advancing its own pipeline of oncology and immunotherapy candidates.
Oncotelic's move aligns with broader trends in the industry toward outsourcing and digitalization. The global biopharmaceutical manufacturing services market is projected to grow substantially, driven by demand for biologics, cell and gene therapies, and personalized medicine. AI and automation are increasingly seen as key enablers of efficiency and quality in this space. Oncotelic's platform positions it at the intersection of these trends, potentially offering a competitive advantage.
Investors can find the latest news and updates regarding OTLC in the company's newsroom at https://ibn.fm/OTLC. Oncotelic's announcement highlights the growing role of artificial intelligence in biopharmaceutical manufacturing and the importance of accessible GMP infrastructure for innovation.
